| 1 |
35222709 | Combination treatment with sorafenib and wh-4 additively suppresses the proliferation of liver cancer cells. | 2022 Mar |
3 |
| 2 |
35244188 | DYRK1A suppression attenuates HIF‑1α accumulation and enhances the anti‑liver cancer effects of regorafenib and sorafenib under hypoxic conditions. | 2022 Apr |
1 |
| 3 |
35252007 | Chenodeoxycholic Acid Enhances the Effect of Sorafenib in Inhibiting HepG2 Cell Growth Through EGFR/Stat3 Pathway. | 2022 |
2 |
| 4 |
35495118 | Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma. | 2022 |
1 |
| 5 |
34277607 | Oxidative Stress Activated by Sorafenib Alters the Temozolomide Sensitivity of Human Glioma Cells Through Autophagy and JAK2/STAT3-AIF Axis. | 2021 |
7 |
| 6 |
34638417 | Optimization and Validation of a Novel Three-Dimensional Co-Culture System in Decellularized Human Liver Scaffold for the Study of Liver Fibrosis and Cancer. | 2021 Sep 30 |
1 |
| 7 |
34885140 | Mitochondrial Plasticity Promotes Resistance to Sorafenib and Vulnerability to STAT3 Inhibition in Human Hepatocellular Carcinoma. | 2021 Nov 30 |
3 |
| 8 |
32103983 | LncRNA DANCR Promotes Sorafenib Resistance via Activation of IL-6/STAT3 Signaling in Hepatocellular Carcinoma Cells. | 2020 |
2 |
| 9 |
32300243 | Synergistic antitumor activity of sorafenib and artesunate in hepatocellular carcinoma cells. | 2020 Dec |
3 |
| 10 |
32913557 | Carnosic acid increases sorafenib-induced inhibition of ERK1/2 and STAT3 signaling which contributes to reduced cell proliferation and survival of hepatocellular carcinoma cells. | 2020 Aug 18 |
1 |
| 11 |
33061451 | IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells. | 2020 |
4 |
| 12 |
33163284 | Sorafenib increases tumor treating fields-induced cell death in glioblastoma by inhibiting STAT3. | 2020 |
6 |
| 13 |
33273830 | Erratum: IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Corrigendum]. | 2020 |
1 |
| 14 |
30761258 | Regorafenib reverses HGF-induced sorafenib resistance by inhibiting epithelial-mesenchymal transition in hepatocellular carcinoma. | 2019 Feb |
2 |
| 15 |
29113744 | Corrigendum to "Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity" [Eur. J. Med. Chem. 55 (2012) 220-227]. | 2018 Jan 1 |
1 |
| 16 |
29782854 | Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT. | 2018 Aug 5 |
1 |
| 17 |
29805309 | Chemical and genetic inhibition of STAT3 sensitizes hepatocellular carcinoma cells to sorafenib induced cell death. | 2018 |
12 |
| 18 |
29953970 | Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-β/STAT3 Pathway. | 2018 |
3 |
| 19 |
30106087 | Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK. | 2018 Nov |
2 |
| 20 |
30277836 | Sorafenib inhibits caspase-1 expression through suppressing TLR4/stat3/SUMO1 pathway in hepatocellular carcinoma. | 2018 |
2 |
| 21 |
30499465 | Rho GTPase Activating Protein 24 (ARHGAP24) Regulates the Anti-Cancer Activity of Sorafenib Against Breast Cancer MDA-MB-231 Cells via the Signal Transducer and Activator of Transcription 3 (STAT3) Signaling Pathway. | 2018 Nov 30 |
5 |
| 22 |
27668844 | Sorafenib with ASC-J9® synergistically suppresses the HCC progression via altering the pSTAT3-CCL2/Bcl2 signals. | 2017 Feb 1 |
4 |
| 23 |
27841868 | Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma. | 2017 Apr 6 |
2 |
| 24 |
28069352 | Corrigendum to "Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma". | 2017 Mar |
1 |
| 25 |
28077164 | Erratum to: Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. | 2017 Jan 11 |
1 |
| 26 |
28084011 | Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells. | 2017 Mar |
1 |
| 27 |
28237700 | Prostaglandin E1 reduces the keratinocyte toxicity of sorafenib by maintaining signal transducer and activator of transcription 3 (STAT3) activity and enhancing the cAMP response element binding protein (CREB) activity. | 2017 Apr 1 |
8 |
| 28 |
28302383 | Erratum to: Corrigendum to "Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma". | 2017 Jun |
1 |
| 29 |
28627705 | Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma. | 2017 Aug |
2 |
| 30 |
28867735 | Effects of Ascorbyl-2-phosphate Magnesium on Human Keratinocyte Toxicity and Pathological Changes by Sorafenib. | 2017 |
1 |
| 31 |
29029413 | Targeting SHP-1-STAT3 signaling: A promising therapeutic approach for the treatment of cholangiocarcinoma. | 2017 Sep 12 |
1 |
| 32 |
26911335 | Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTPε and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma. | 2016 Feb 25 |
1 |
| 33 |
26956050 | Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells. | 2016 Apr 12 |
1 |
| 34 |
26971793 | Inhibition of Autophagy by Chloroquine Enhances the Antitumor Efficacy of Sorafenib in Glioblastoma. | 2016 Oct |
1 |
| 35 |
25043125 | Inhibition of myeloid cell leukemia-1: Association with sorafenib-induced apoptosis in human mucoepidermoid carcinoma cells and tumor xenograft. | 2015 Sep |
2 |
| 36 |
26039995 | Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition. | 2015 Jun 9 |
5 |
| 37 |
26154152 | Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma. | 2015 Oct |
1 |
| 38 |
26297434 | Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner. | 2015 Jul |
5 |
| 39 |
23908138 | Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma. | 2014 Jan |
4 |
| 40 |
24309512 | Multi-kinase inhibition in ovarian cancer. | 2014 Jan |
1 |
| 41 |
24418169 | YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma. | 2014 Jan 13 |
7 |
| 42 |
24736071 | Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer. | 2014 Apr |
1 |
| 43 |
25013907 | Association of toxicity of sorafenib and sunitinib for human keratinocytes with inhibition of signal transduction and activator of transcription 3 (STAT3). | 2014 |
10 |
| 44 |
25047655 | SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma. | 2014 Jul |
9 |
| 45 |
25057499 | Hepatic stellate cell coculture enables sorafenib resistance in Huh7 cells through HGF/c-Met/Akt and Jak2/Stat3 pathways. | 2014 |
3 |
| 46 |
25386075 | Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy. | 2014 Nov 7 |
5 |
| 47 |
22978563 | Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody. | 2013 Feb |
5 |
| 48 |
23392173 | Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells. | 2013 Feb 7 |
5 |
| 49 |
23474115 | Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3. | 2013 Jul 1 |
6 |
| 50 |
23938089 | Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells. | 2013 |
5 |